Chemo Therapy Failure

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By Malecare|2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment

On The Horizon – Some More Information & An Update On MDV3100

Many of us are aware of the newly approved drug Zytiga (abiraterone). It had demonstrated a survival advantage for men who are castrate resistant and failed chemotherapy. Zytiga was approved by the FDA in April and many of us with advanced prostate cancer have been taking advantage of the drug. You can learn more about [...]

By Malecare|2017-10-19T10:51:59-04:00October 16th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|2 Comments

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

By Malecare|2011-10-04T15:33:19-04:00October 4th, 2011|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), bisphosphonates, Cabazitaxel, Chemo Therapy Failure, Clinical Trials, Clinical Trials, denosumab - Xgeva, Drugs & Treatments, On The Horizon, Uncategorized, Zometa|1 Comment

Identifying A New Pathway Explaining Resistance to Prostate Cancer Treatment

We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to treatment with antiandrogens (ADT) such as Lupron or Zoladex is not limited just to this class of drugs. We have [...]

By Malecare|2017-10-19T10:52:07-04:00August 18th, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|10 Comments

A Provenge Like Treatment Demonstrates Extraordinary Results Treating Leukemia – A Phase I Trial Using the Technique In Post Chemo Prostate Cancer Treatment

The most exciting news today is about some research performed at the University of Pennsylvania where researchers took blood from the three leukemia patients and isolated the T cells, a type of immune cell in the blood. T cells recognize invading organisms and kill them, however they do not recognize cancer cells as invading cells, [...]

By Malecare|2020-02-04T11:34:16-05:00August 12th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC, vaccines|2 Comments

Using Zytiga Prior to Chemotherapy, Is It A Good Idea?

It is interesting that Dr. S. Meyers just produced a video on the issue of using the newly approved drug Zytiga (abiraterone acetate) prior to chemotherapy instead of post-chemotherapy. I find it interesting because like him, I have been receiving a number of questions about this same issue. […]

By Malecare|2020-02-04T10:37:30-05:00August 4th, 2011|2nd line hormone therapy, abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|6 Comments

An Official Release of the Exciting Results of the Abiraterone Acetate (Zytiga) Trial

Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]

By Malecare|2017-10-19T10:52:35-04:00May 27th, 2011|abiraterone acetate, Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized|0 Comments

New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

By Malecare|2011-05-06T11:30:13-04:00May 6th, 2011|abiraterone acetate, Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, General Information, How We Live, On The Horizon, Prostate Ponderings, Provenge, Research, TAK700, Uncategorized, Understanding APC|3 Comments

Carboplatin – A 2nd line chemotherapy?

Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Currently, it is approved by the Food & Drug Administration (FDA) for treating patients with ovarian and non-small cell lung cancer. However, some oncologists use carboplatin “off-label” for other cancers. Commonly, these “off-label” uses include testicular, stomach, and bladder cancers as well [...]

By Malecare|2021-02-17T11:03:29-05:00April 1st, 2011|Advanced Prostate Cancer, carboplatin, Chemo Therapy Failure, Clinical Trials, End-Of-Life, salvage therapy, Uncategorized|1 Comment

More Good Data Supporting the Approval of Abiraterone

As we all anxiously wait for the FDA to finally make a determination about the pending application for approval of the investigational androgen biosynthesis inhibitor abiraterone acetate more data rolls in showing that supports the need to have a speedy approval. A new study published March 1, 2011, out of Italy adds support to the [...]

By Malecare|2017-10-19T10:53:15-04:00March 21st, 2011|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, Uncategorized, Understanding APC, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments